About CBI

CBI offers cutting-edge research and development products and services to the global life sciences industry. CBI now operates solely through Mimotopes Pty Ltd, Melbourne, Australia, a peptide and discovery chemistry business.

Forward Looking Statements

No statement made in this press release should be interpreted as an offer to purchase any security. Such an offer can only be made in accordance with the Securities Act of 1933, as amended and applicable state securities laws. Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in CBI's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially. Specifically, CBI cannot guaranty that the company:

• will be able to find a buyer for the Richmond real estate under terms acceptable to the company;
• will be able to find a buyer for Mimotopes Pty Ltd under terms acceptable to the company;
• will be able to find a company to merge with under terms acceptable to the company, and;
• CBI's shareholders and lenders will approve any of these transactions.

Readers are cautioned not to place undo reliance on these forward-looking statements, which speak only as the date hereof. Further, all forward-looking statements included in this press release are based upon information available to CBI as of the date hereof. CBI assumes no obligation to update any such forward-looking statements.

Contact: Commonwealth Biotechnologies, Inc.
Richard J. Freer, Ph.D., CEO, 804 464 1601

转载自pharmaLive